💧 On a Statin — What It Moves and What It Misses

What this panel can settle, and by what logic

Seven markers that between them answer four separate questions about one prescription: is it working, what is it costing, what is it not touching, and is the muscle complaint plausible.

1. ApoB (Apolipoprotein B) beside the Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) answers is it working, properly. LDL cholesterol estimates the cholesterol carried inside particles; ApoB counts the particles, one molecule per particle. In statin-treated patients, ApoB and non-HDL cholesterol reflected residual risk better than LDL cholesterol did Johannesen 2021, and the two diverge most in people with high triglycerides and metabolic syndrome, who are exactly the people most likely to be on the drug.
2. Lipoprotein(a) — Lp(a) answers what it is not touching. Lipoprotein(a) is largely genetically determined, it is not lowered by statins, and the case for measuring it once has been made explicitly in the lipid literature Nurmohamed 2023. Somebody with a perfect LDL, a perfect ApoB and a high Lp(a) still carries the risk, and this is the one marker on the panel that never needs repeating.
3. HbA1c (Hemoglobin A1c) answers what it is costing, with a real number. An individual participant data meta-analysis of blinded statin trials found a 10% proportional increase in new-onset diabetes on low or moderate-intensity statins and a 36% proportional increase on high-intensity therapy, with mean glucose rising 0.04 mmol/L and mean HbA1c 0.06% on low or moderate intensity Cholesterol Treatment Trialists' (CTT) Collaboration 2024. That is small in absolute terms, concentrated in people already near the threshold, and a reason to measure rather than a reason to stop.
4. Coenzyme Q10 answers the mechanism half of the muscle question. Statins inhibit HMG-CoA reductase, which sits upstream of both cholesterol and coenzyme Q10, so the fall in CoQ10 is a predicted consequence of how the drug works rather than an idiosyncratic reaction. Statin therapy has measurably lowered plasma concentrations of fat-soluble antioxidants carried on the same lipoproteins Motkowski 2022.
5. Comprehensive Metabolic Panel (CMP) and hs-CRP (High-Sensitivity C-Reactive Protein) carry the routine half. Transaminases decide whether a repeat is needed rather than a stop, and CRP reads the anti-inflammatory effect that is part of why the drug works.

The discrimination the set buys: LDL at target with ApoB still high. That combination means the particle count has not fallen even though the cholesterol has, and it is invisible on the lipid panel a prescription is normally judged by Johannesen 2021.

What it cannot settle, and what would

It cannot diagnose statin myopathy, and that is the commonest reason somebody buys a panel like this. Creatine kinase is the test for muscle injury and it is not in this catalog, so a genuine myopathy question needs a CK ordered through a clinician. Measuring Coenzyme Q10 measures the mechanism most often blamed; it does not measure the muscle.

And measuring CoQ10 will not tell you whether supplementing it helps. A double-blinded randomized placebo-controlled trial gave 400 mg of CoQ10 or placebo daily for eight weeks to 37 people on simvastatin with and without myalgia Dohlmann 2022, and the systematic reviews of this question have not produced a consistent benefit Kovacic 2025. A low CoQ10 explains a plausible mechanism and does not predict a response to replacing it. That is worth knowing before spending $80 to find out.

It cannot rule out the other causes of muscle ache, which include hypothyroidism and vitamin D deficiency, both cheap to exclude and both far more likely to respond to treatment than a CoQ10 result.

And it cannot decide whether you should be on a statin. That is an absolute risk calculation using age, blood pressure, smoking, diabetes and family history alongside the lipids, and the risk of stopping a statin after a cardiovascular event is not symmetrical with the risk of a slightly higher HbA1c Cholesterol Treatment Trialists' (CTT) Collaboration 2024.

Draw conditions that decide whether the money is wasted

Four conditions, and one of them is about not wasting money on a repeat.

1. Wait at least 6 weeks after starting or changing the dose. Statin lipid effects plateau at roughly 4 to 6 weeks, so an earlier draw understates the response and invites a dose increase that was not needed.
2. Fast 9 to 12 hours. Triglycerides are the most meal-sensitive number on the Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and they feed the calculated LDL, which is the number a prescriber will compare against the target.
3. Lipoprotein(a) — Lp(a) needs no fasting and no repeat. One lifetime measurement is the standard position, and repeating it is the commonest avoidable waste on this panel Nurmohamed 2023.
4. Not within 2 weeks of an illness or an endurance event. Both distort lipids and raise hs-CRP (High-Sensitivity C-Reactive Protein), and a marathon raises muscle enzymes for days, which is the exact confusion this panel is trying to avoid.

How you would know it answered your question, and what each pattern means next

Five results and their branch points.

• ApoB (Apolipoprotein B) down in step with LDL on the Lipid Panel (Cholesterol, HDL, LDL, Triglycerides): the drug is doing its job. Retest at 12 months unless the dose changes, and at 6 to 8 weeks after any change Johannesen 2021.
• LDL at target, ApoB still above it: discordance. The particle count is what tracks the risk, so this is a conversation about intensifying rather than a reason to relax Johannesen 2021. Retest ApoB 8 weeks after any change.
• High Lipoprotein(a) — Lp(a) with everything else at target: residual risk that is genetic. It changes the intensity of everything else and it makes first-degree relatives worth testing, and it never needs remeasuring Nurmohamed 2023.
• HbA1c (Hemoglobin A1c) drifting up on treatment: expected in a minority and managed rather than a reason to stop Cholesterol Treatment Trialists' (CTT) Collaboration 2024. Retest HbA1c at 6 months, since it reflects roughly the preceding 3 months and a shorter interval reads the old value.
• Transaminases raised on the Comprehensive Metabolic Panel (CMP): repeat before concluding. A single mild elevation is common and frequently resolves; a persistent or rising one is a prescriber's decision.

The result that settles the muscle question in the honest direction: a normal Coenzyme Q10 alongside muscle aches means the mechanism most often blamed is not present in you, and the next tests are thyroid function and vitamin D rather than a CoQ10 supplement Kovacic 2025.

Sources read for these sections

• Johannesen CDL, et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology 2021 · PMID 33736827
• Cholesterol Treatment Trialists' (CTT) Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes & Endocrinology 2024 · PMID 38554713
• Dohlmann TL, et al. Coenzyme Q10 Supplementation in Statin Treated Patients: A Double-Blinded Randomized Placebo-Controlled Trial. Antioxidants (Basel) 2022 · PMID 36139772
• Kovacic S, et al. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. Journal of Nutritional Science 2025 · PMID 41158831
• Nurmohamed NS, et al. Considerations for routinely testing for high lipoprotein(a). Current Opinion in Lipidology 2023 · PMID 35942815
• Motkowski R, et al. Effect of Statin Therapy on the Plasma Concentrations of Retinol, Alpha-Tocopherol and Coenzyme Q10 in Children with Familial Hypercholesterolemia. Cardiovascular Drugs and Therapy 2022 · PMID 33052507